Phase 3
Completed N=511
Experimental Medication For the Treatment of Generalized Anxiety Disorder
Source: ClinicalTrials.gov NCT00097708 ↗Enrolled (actual)
511
Serious AEs
1.4%
Results posted
Oct 2014
Primary outcomePrimary: Change in HAM-A Total Score — -12.9; -15.7; -12.5 Units on a Scale — p=0.6540
Summary
The purpose of this study is to determine whether an experimental anti-anxiety medication is effective in the treatment of Generalized Anxiety Disorder.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in HAM-A Total Score |
-12.9; -15.7; -12.5 | 0.6540 |
Eligibility Criteria
Inclusion Criteria
- Subjects 18 to 65 years of age will be eligible to participate if they satisfy the DSM-IV-TR criteria for the diagnosis of GAD.
Exclusion Criteria
- No other primary psychiatric diagnosis besides GAD.
Data sourced from ClinicalTrials.gov (NCT00097708). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.